BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16995478)

  • 1. Preoperative IL-2 immunotherapy enhances tumor infiltrating lymphocytes (TILs) in gastric cancer patients.
    Romano F; Cesana G; Caprotti R; Bovo G; Uggeri F; Piacentini MG; Crippa S; Uggeri F
    Hepatogastroenterology; 2006; 53(70):634-8. PubMed ID: 16995478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
    J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F; Piacentini MG; Franciosi C; Caprotti R; De Fina S; Cesana G; Uggeri F; Conti M; Uggeri F
    Hepatogastroenterology; 2004; 51(60):1872-6. PubMed ID: 15532847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis.
    Cesana GC; Romano F; Piacentini G; Scotti M; Brenna A; Bovo G; Vaghi M; Aletti G; Caprotti R; Kaufman H; Uggeri F
    Ann Surg Oncol; 2007 Apr; 14(4):1295-304. PubMed ID: 17225981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical surgery does not recover immunodeficiency associated with gastric cancer.
    Romano F; Caprotti R; Bravo AF; Conti M; Colombo G; Piacentini G; Uggeri F; Uggeri F
    J Exp Clin Cancer Res; 2003 Jun; 22(2):179-83. PubMed ID: 12866567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
    Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative interleukin-2 immunotherapy in pancreatic cancer: preliminary results.
    Angelini C; Bovo G; Muselli P; Mussi C; Crippa S; Caprotti R; Uggeri F
    Hepatogastroenterology; 2006; 53(67):141-4. PubMed ID: 16506394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy in radical surgery of colorectal carcinoma].
    Brivio F; Fumagalli L; Chiarelli M; Denova M; Bertolini A; Cetta M; Nespoli A
    Chir Ital; 2007; 59(5):635-40. PubMed ID: 18019635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
    Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
    Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunodeficiency in different histotypes of radically operable gastrointestinal cancers.
    Romano F; Uggeri F; Crippa S; Di Stefano G; Scotti M; Scaini A; Caprotti R; Uggeri F
    J Exp Clin Cancer Res; 2004 Jun; 23(2):195-200. PubMed ID: 15354402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immunotherapy and spleen preservation on immunological function in patients with gastric cancer.
    Okinaga K; Iinuma H; Kitamura Y; Yokohata T; Inaba T; Fukushima R
    J Exp Clin Cancer Res; 2006 Sep; 25(3):339-49. PubMed ID: 17167974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
    Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
    Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer.
    Lu P; Zhu XQ; Xu ZL; Zhou Q; Zhang J; Wu F
    Surgery; 2009 Mar; 145(3):286-93. PubMed ID: 19231581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
    Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study.
    Franciosi CM; Piacentini MG; Conti M; Romano F; Musco F; Caprotti R; Rovelli F; Uggeri F
    Hepatogastroenterology; 2003; 50(49):297-300. PubMed ID: 12630045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
    Tímár J; Ladányi A; Forster-Horváth C; Lukits J; Döme B; Remenár E; Godény M; Kásler M; Bencsik B; Répássy G; Szabó G; Velich N; Suba Z; Elo J; Balatoni Z; Pócza K; Zemplén B; Chretien P; Talor E
    J Clin Oncol; 2005 May; 23(15):3421-32. PubMed ID: 15908653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study.
    Kapoor S; Pal S; Sahni P; Dattagupta S; Kanti Chattopadhyay T
    J Surg Res; 2005 Dec; 129(2):172-5. PubMed ID: 15882879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
    Gao Q; Qiu SJ; Fan J; Zhou J; Wang XY; Xiao YS; Xu Y; Li YW; Tang ZY
    J Clin Oncol; 2007 Jun; 25(18):2586-93. PubMed ID: 17577038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
    Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
    Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.
    Gardini A; Ercolani G; Riccobon A; Ravaioli M; Ridolfi L; Flamini E; Ridolfi R; Grazi GL; Cavallari A; Amadori D
    J Surg Oncol; 2004 Jul; 87(1):46-52. PubMed ID: 15221919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.